Balance Sheet
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioEnterprise ValueInventory AverageInvested Capital

Telix Pharmaceuticals (TLX) Enterprise Value (2024 - 2026)

Telix Pharmaceuticals has reported Enterprise Value over the past 3 years, most recently at -$141.9 million for Q4 2025.

  • Quarterly Enterprise Value rose 69.46% to -$141.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$141.9 million through Dec 2025, up 69.46% year-over-year, with the annual reading at -$141.9 million for FY2025, 69.46% up from the prior year.
  • Enterprise Value was -$141.9 million for Q4 2025 at Telix Pharmaceuticals, up from -$464.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$80.2 million in Q4 2023 and troughed at -$464.5 million in Q4 2024.
  • The 3-year median for Enterprise Value is -$141.9 million (2025), against an average of -$228.9 million.
  • Year-over-year, Enterprise Value crashed 479.03% in 2024 and then soared 69.46% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$80.2 million in 2023, then crashed by 479.03% to -$464.5 million in 2024, then soared by 69.46% to -$141.9 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Enterprise Value are -$141.9 million (Q4 2025), -$464.5 million (Q4 2024), and -$80.2 million (Q4 2023).